SAN DIEGO, Feb. 18, 2020 /PRNewswire/ -- Viracta Therapeutics, Inc. (the `Company`), a precision oncology company targeting virus-associated malignancies, announced today that Ivor Royston, M.D., the Company`s President and CEO, will present an overview of Viracta`s approach in treating patients with Epstein-Barr Virus (EBV)-associated malignancies and data from the ongoing Phase 2 clinical trial in lymphoma. It is estimated that there are over 200,000 new cases of EBV-associated cancers each year. Scientific research has worked to better understand these diseases and develop novel therapeutic approaches to address this global unmet need, however, there are no approved...
|
